Summary

  • A Wall Street Journal Heard on the Street analysis by David Wainer attributed Oura’s shelved late-September initial public offering to a divergence between the “health intelligence platform” framing in the company’s prospectus and how prospective investors valued the underlying hardware business.
  • About 80% of Oura’s revenue still comes from ring sales and 20% from memberships, with the company asking for a valuation of up to $15 billion at roughly 10 times trailing revenue on a gross margin of about 55%.
  • University of Florida finance professor Jay Ritter’s study of 13 single-product consumer IPOs from 2005 to 2024 found those shares lost an average of 32% over five years, against a 49% rise in the broader market and a 68% average gain for more than 1,200 other IPOs in the same sample.
  • The WSJ analysis identified the third-payer pathway — employers, insurers, and drugmakers paying for the underlying biometric data — as the most promising breakout route, with Eli Lilly’s pre-IPO investment and reported acquisition interest signaling one potential buyer.

A Wall Street Journal Heard on the Street analysis published Tuesday identified a different obstacle to Oura’s shelved late-September initial public offering than the one the company named at the time. The smart-ring maker blamed jittery markets. The analysis by David Wainer pointed to a structural mismatch between the “health intelligence platform” Oura described in its prospectus — built on more than 40 billion hours of biometric data — and how prospective investors valued the underlying business, treating it as a consumer-gadget company. About 80% of the company’s revenue still comes from ring sales and 20% from memberships, the analysis reported, with a gross margin of about 55% and a price tag of up to $15 billion — roughly 10 times trailing revenue. The combination, the analysis argued, sat uneasily in a market accustomed to applying software-like multiples only to businesses with software-like economics.

The prospectus-versus-economics gap

The prospectus pitch and the unit economics, as the WSJ analysis assembled them, describe different businesses. The prospectus described a “health intelligence platform” with potential to layer software and artificial intelligence on top of a data asset. The analysis reported a 20% subscription mix, a gross margin of about 55% — well below what digital-health software companies typically earn — and a marketing budget the analysis placed at about a fifth of revenue, spent to sell new rings each year. Fitbit, by comparison, was sold to Google for less than two times revenue. Robin Boldt, chief investment officer at healthcare-focused hedge fund Rock2 Capital, told the WSJ: “Hardware-centric businesses naturally demand a lower sales multiple. The ability to sustain and even accelerate subscription growth would make public investors more comfortable.” The analysis added that surging Treasury yields were “certainly part of the problem” the company cited at the time, but did not treat macro volatility as the durable obstacle.

The category-signal evidence

The analysis placed Oura in a category with a documented five-year track record. Jay Ritter, a University of Florida professor who studies IPOs, tracked 13 single-product consumer issuers that went public between 2005 and 2024. Five years after listing, their shares had lost an average of 32% from the IPO price, while the broader market rose 49% over the same period. More than 1,200 other IPOs in Ritter’s sample gained an average of 68% over their first five years. The analysis named Peloton, Fitbit, Casper Sleep, and GoPro as buzzy consumer hardware brands that built recognizable brands quickly and then encountered the same constraint — that revenue growth required continuously selling more hardware. “The consumer wallet,” Stephanie Davis, a health-tech analyst and adviser, told the WSJ, “is a very quick adopter of solutions and a very quick abandoner of solutions.”

The subscription lock-in question

Oura does have a recurring component, the analysis noted: more than five million members pay about $6 a month, and the company says 85% stick around after a year. The analysis observed, however, that successful platforms tend to be built on dependence — developers make a living on Apple’s App Store, drivers and restaurants rely on Uber — while leaving Oura costs a subscriber “little more than their sleep history.” That distinction, the analysis argued, is what separates a recurring-revenue business from a platform, and what determines whether the multiple a company can command resembles one category or the other.

Three breakout paths the analysis identified

The WSJ analysis outlined three routes single-product companies have used to break out of the cycle. Garmin, best known for car GPS units before smartphones largely destroyed that business, pivoted to fitness watches, outdoor gear, and aviation and marine electronics. Roku, the only single-product maker in Ritter’s sample to beat the market, sells streaming players at thin margins and makes money from advertising and a cut of subscriptions; Fox Corp. agreed to acquire Roku in June in a $25 billion deal. The third route, the analysis suggested, is to get someone other than the consumer to pay: patients receive ResMed’s CPAP machines and Dexcom’s glucose monitors largely because insurers cover them, and Hinge Health, which offers app-based physical therapy for back and joint pain, is paid mostly by employers and health plans.

The healthcare-buyer hypothesis

The analysis identified the third path as the most promising for Oura, and described a sale as potentially the easiest route for shareholders. “A tech company could theoretically buy Oura,” the analysis noted, “but a healthcare giant might be the more natural owner” — the implication being that the biometric data is most valuable to a payer or a drugmaker rather than to a consumer-electronics buyer. Eli Lilly invested in Oura before the shelved IPO and had indicated interest in acquiring more, the analysis reported; Lilly could see value in knowing whether patients on its weight-loss drugs Zepbound and Mounjaro are sleeping better, moving more, and improving other health measures. The analysis suggested the wider category implication applies to wellness hardware startups more broadly, including Whoop.

What happens next

Oura has some of the third-payer infrastructure already, the analysis noted: its temperature data feeds Natural Cycles, a fertility app, and employers spend heavily on fertility care. The missing evidentiary step, the analysis added, is showing payers that wearing the ring improves health outcomes, not just that it measures them accurately. The structural constraint — a hardware-heavy revenue mix with a recurring but not yet dependent subscription base, and the resulting need to spend roughly a fifth of revenue on marketing each year — would reappear in any market environment, the analysis implied. The analysis concluded that Oura “does not need to become the next Apple or even the next Garmin” and instead “needs to prove that the data it collects is valuable to someone other than the consumer — and that it does more than sell expensive rings.” Whether the company finds that proof before returning to the public market, or finds a buyer first, is the open question the analysis left.

Additional considerations

Oura’s cap table is not detailed in the source materials, so internal-shareholder sub-interests — including how heavily existing venture investors are pushing for a sale versus a relisting at a lower valuation — cannot be separately mapped. The published WSJ figures, including the 32%, 49%, and 68% averages in Ritter’s sample, the sub-two-times Fitbit revenue multiple, the $25 billion Fox-Roku deal, and the up-to-$15 billion proposed Oura valuation, trace to the source article and the Tier 1 publication metadata associated with it; the source article is the source of truth for those numbers. The most direct comparison class for Oura’s post-listing trajectory, if the hardware constraint persists, remains the 13 single-product consumer issuers in Ritter’s sample; if the third-payer path lands, the comparison class becomes ResMed, Dexcom, and Hinge Health rather than Peloton and GoPro.

Analytical techniques used in this piece

This analysis applies the methods below. Each links to a short, plain-English explainer you can read and reuse.

Interest Mapping
Separates parties’ stated positions from their underlying interests (Fisher & Ury).
Root-Cause Analysis
Traces a symptom back along its causal chain to the conditions that actually generated it.
Stakeholder Mapping
Charts the parties to a situation — their interests, power, and alignments.